# Silence Therapeutics to Present at Jefferies Healthcare Conference

6/2/2022

LONDON--(BUSINESS WIRE)-- Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today announced that the Company will present at the Jefferies Healthcare Conference on Thursday, June 9th at 10:00 a.m. EDT / 2:00 p.m. GMT.

A live webcast of the presentation can be accessed via the Investors section of the Silence website at **www.silence-therapeutics.com**. An archived replay of the webcast will be available on the Company’s website following the conference.

## About Silence Therapeutics

Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, to inhibit the expression of specific target genes thought to play a role in the pathology of diseases with significant unmet need. Silence's proprietary mRNAi GOLD™ platform can be used to create siRNAs (short interfering RNAs) that precisely target and silence disease-associated genes in the liver, which represents a substantial opportunity. Silence's wholly owned product candidates include SLN360 designed to address the high and prevalent unmet medical need in reducing cardiovascular risk in people born with high levels of lipoprotein(a) and SLN124 designed to address hematological diseases. Silence also maintains ongoing research and development collaborations with AstraZeneca, Mallinckrodt Pharmaceuticals, and Hansoh Pharma, among others. For more information, please visit **https://www.silence-therapeutics.com/**.

View source version on **businesswire.com**: **https://www.businesswire.com/news/home/20220602005054/en/**


## Silence Therapeutics plc

Gem Hopkins, Head of IR and Corporate Communications

**ir@silence-therapeutics.com**
Tel: +1 (646) 637-3208

Source: Silence Therapeutics plc